α-(p-Chlor-benzolsulfonylamino)-propionylchlorid | 108130-14-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: α-(p-Chlor-benzolsulfonylamino)-propionylchlorid
• 英文别名: N-[(4-chloro-phenyl)sulfonyl]alanyl chloride；2-[(4-Chlorophenyl)sulfonylamino]propanoyl chloride
• CAS: 108130-14-9
• 化学式: C₉H₉Cl₂NO₃S
• 分子量: 282.147
• InChiKey: GGPTVPAYPGUYNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  α-(p-Chlor-benzolsulfonylamino)-propionylchlorid 在 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 4.17h， 生成 4-chloro-N-(1-methyl-2-oxo-pentyl)-benzenesulfonamide
  参考文献：
  名称：

  WO2007/129019

  摘要：

  公开号：
• 作为产物：
  描述：

  N-[(4-氯苯基)磺酰基]丙氨酸 在 氯化亚砜 作用下， 生成 α-(p-Chlor-benzolsulfonylamino)-propionylchlorid
  参考文献：
  名称：

  WO2008/59238

  摘要：

  公开号：

文献信息

• SULFONAMIDE COMPOUNDS USEFUL AS ADG RECEPTOR MODULATORS
  申请人：Grewal Gurmit

  公开号：US20090111860A1

  公开（公告）日：2009-04-30

  The present invention relates to compounds of formula (I) that mediate Edg, including Edg-1, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant vascularization or inflammatory component such as in tumor-related diseases. The present invention also relates to compounds that inhibit a5bl, and also that exhibit appropriate selectivity profile(s) against other integrins.

  本发明涉及公式（I）的化合物，其介导Edg，包括Edg-1，其制备方法，包含它们作为活性成分的制药组合物，它们作为药物的用途以及它们用于制造用于治疗具有显著血管化或炎症成分的疾病的药物，如肿瘤相关疾病。本发明还涉及抑制a5bl的化合物，以及对其他整合素具有适当选择性谱的化合物。
• PROCESS FOR PRODUCING OPTICALLY ACTIVE IMIDAZOLE COMPOUNDS, INTERMEDIATES FOR SYNTHESIZING THE SAME, AND PROCESS FOR PRODUCING THE SAME
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0972768A1

  公开（公告）日：2000-01-19

  The present invention provides a method for producing an optically active 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid or a pharmaceutically acceptable salt thereof, which includes subjecting a compound of the formula (I) wherein each symbol in the formula is as defined in the specification, to optical resolution by fractional crystallization to give an optically active compound thereof and subjecting the compound to hydrolysis reaction. According to this method, a resolution method useful for industrial large-scale production of the optically active compound of 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid, which is useful as a thromboxane synthetase inhibitor and an agent for the prophylaxis and treatment of diabetic complications, can be obtained.

  本发明提供了一种生产光学活性 4-[α-羟基-5-(1-咪唑基)-2-甲基苄基]-3,5-二甲基苯甲酸或其药学上可接受的盐的方法，该方法包括将式(I)化合物 其中式中各符号如说明书中所定义，通过分馏结晶进行光学解析，得到其光学活性化合物，并使该化合物进行水解反应。根据该方法，可以获得一种用于工业化大规模生产 4-[α-羟基-5-(1-咪唑基)-2-甲基苄基]-3,5-二甲基苯甲酸光学活性化合物的解析方法，该化合物可用作血栓素合成酶抑制剂和预防及治疗糖尿病并发症的药物。
• Process for producing optically active imidazole compounds, intermediates for synthesizing the same, and process for producing the same
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1378507A2

  公开（公告）日：2004-01-07

  The present invention provides a method for producing an optically active 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid or a pharmaceutically acceptable salt thereof, which includes subjecting a compound of the formula (I) wherein each symbol in the formula is as defined in the specification, to optical resolution by fractional crystallization to give an optically active compound thereof and subjecting the compound to hydrolysis reaction. According to this method, a resolution method useful for industrial large-scale production of the optically active compound of 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid, which is useful as a thromboxane synthetase inhibitor and an agent for the prophylaxis and treatment of diabetic complications, can be obtained.

  本发明提供了一种生产光学活性 4-[α-羟基-5-(1-咪唑基)-2-甲基苄基]-3,5-二甲基苯甲酸或其药学上可接受的盐的方法，该方法包括将式(I)化合物 其中式中各符号如说明书中所定义，通过分馏结晶进行光学解析，得到其光学活性化合物，并使该化合物进行水解反应。根据该方法，可以获得一种用于工业化大规模生产 4-[α-羟基-5-(1-咪唑基)-2-甲基苄基]-3,5-二甲基苯甲酸光学活性化合物的解析方法，该化合物可用作血栓素合成酶抑制剂和预防及治疗糖尿病并发症的药物。
• Process for producing optically active imidazole derivatives, intermediates and synthesis thereof
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1378507B1

  公开（公告）日：2006-08-23
• SULFONAMIDE COMPOUNDS USEFUL AS EDG RECEPTOR MODULATORS
  申请人：AstraZeneca AB

  公开号：EP2013184A1

  公开（公告）日：2009-01-14